TEM — Tempus AI, Inc.
Is TEM overbought or oversold? Here is the current MarketMoodz read.
Tempus AI, Inc. (TEM) currently reads Strong Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Health Information Services) last closed at $64.76. The rating moved from Overbought to Strong Oversold on November 14, 2026.
- Public ratingStrong Oversold (as of November 17, 2026)
- Last close$64.76
- Last changeMoved from Overbought to Strong Oversold on November 14, 2026
- SectorHealthcare
- IndustryHealth Information Services
See all oversold Healthcare stocks →
AI analysis
Tempus leverages a growing clinical and biopharma services footprint plus proprietary data and AI to address a large oncology/precision‑medicine market. Revenue diversification across testing, pathology and trial services and expanding commercial partnerships underpin growth prospects. Near‑term performance is exposed to reimbursement dynamics, operational scale-up execution, and competition. Absent major new filings or clinical readouts, market sentiment looks cautious; catalysts such as larger biopharma contracts, improved margin trends, or clearer reimbursement pathways would materially improve the outlook.
Key factors
- Differentiated data asset and AI capabilities for oncology and clinical decision support that can drive recurring revenue via diagnostics and software services
- Diverse revenue streams: clinical sequencing, pathology, and biopharma services (clinical trial services, companion diagnostics) supporting growth visibility
- Large addressable market in oncology and precision medicine with accelerating adoption of genomic testing and targeted therapies
- Partnership and collaboration runway with biopharma customers for trial services and real‑world evidence, which can generate higher‑margin revenue
- Operational leverage potential as volume scales and fixed costs spread across higher test throughput and software monetization
Risks
- Reimbursement and regulatory pressure (including Medicare/Medicaid program integrity actions) that could reduce payment rates or increase administrative burden
- Intense competition from established diagnostics and genomics players (including integrated labs and other precision‑medicine vendors) eroding pricing power
- Execution risk: scaling laboratory operations, maintaining quality/control, and converting biopharma collaborations into sustained revenue
- Capital intensity and cash burn risk if topline growth slows before reaching profitability; possible dilution from future financing
- Data privacy, security, and IP risks tied to handling large clinical datasets and AI models
- Macroeconomic and market risk: defensive flows and risk‑off sentiment in the near term could compress multiples and share price volatility
Latest MarketMoodz coverage
See today's live rating, score and targets
Members see the live hourly rating for TEM — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.